FSD Pharma Inc. | WebDisclosure

Basculer en Français

11196	Companies
247755	Keywords
175536	Articles
133879	Press releases

Home
Companies
FSD Pharma Inc.

PRESS RELEASE

published on 03/27/2024 at 13:00, 2 years 6 months ago

FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults
FSD Pharma Inc. announces agreement with iNGENu CRO Pty Ltd. to conduct a Phase 1 clinical study for novel compound Lucid-21-302 to treat MS. Company aims to develop innovative therapeutics

FSD Pharma Inc. Multiple Sclerosis Lucid-21-302 INGENu CRO Pty Ltd. Phase 1 Clinical Study
BRIEF

published on 03/11/2024 at 13:05, 2 years 7 months ago

FSD Pharma annonce la soumission d'une demande d'essai clinique pour la boisson unbuzzd(TM)

FSD Pharma Essai Clinique Métabolisme De L'alcool Produits Biopharmaceutiques Unbuzzd(TM)
BRIEF

published on 03/11/2024 at 13:05, 2 years 7 months ago

FSD Pharma Announces Submission of Clinical Trial Application for unbuzzd(TM) Beverage

FSD Pharma Biopharmaceuticals Clinical Trial Alcohol Metabolism Unbuzzd(TM)
PRESS RELEASE

published on 03/11/2024 at 13:00, 2 years 7 months ago

FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM)
FSD Pharma Inc. submits a Clinical Trial Application for a Phase-1b trial on unbuzzd™, a dietary supplement to assess safety and efficacy in alcohol metabolism. Expert team readies for trial recruitment

FSD Pharma Inc. Unbuzzd™ Alcohol Metabolism Clinical Trial Application Phase-1b Trial
BRIEF

published on 03/05/2024 at 14:05, 2 years 7 months ago

FSD Pharma annonce les résultats positifs de l'étude de phase 1 pour le Lucid-21-302 lors du forum ACTRIMS 2024

FSD Pharma Sclérose En Plaques ACTRIMS 2024 Lucide-21-302 Étude De Phase 1
BRIEF

published on 03/05/2024 at 14:05, 2 years 7 months ago

FSD Pharma Announces Positive Phase-1 Study Results for Lucid-21-302 at ACTRIMS 2024 Forum

FSD Pharma Multiple Sclerosis Lucid-21-302 Phase-1 Study ACTRIMS 2024
PRESS RELEASE

published on 03/05/2024 at 14:00, 2 years 7 months ago

FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
FSD Pharma announces positive results of Lucid-21-302 in Phase-1 clinical study for MS treatment at ACTRIMS 2024 Forum. The presentation covered drug safety, absorption levels, and neuroprotective effects

FSD Pharma Multiple Sclerosis ACTRIMS 2024 Forum Phase-1 Clinical Study Neuroprotective Compound
BRIEF

published on 02/28/2024 at 14:00, 2 years 7 months ago

FSD Pharma Règle des Dettes par Émission d'Actions et Accorde des RSUs

Biopharmaceutique FSD Pharma Émission D'actions Traitement Neurodégénératif RSUs
BRIEF

published on 02/28/2024 at 14:00, 2 years 7 months ago

FSD Pharma Settles Debts through Issuance of Shares and Grants RSUs

FSD Pharma Biopharmaceutical RSUs Issue Of Shares Neurodegenerative Treatment
PRESS RELEASE

published on 02/28/2024 at 14:00, 2 years 7 months ago

FSD Pharma Announces Debt Settlement
FSD Pharma settles debt with shares issuance and grants RSUs to consultants. Company dedicated to biopharmaceutical innovation for neurodegenerative, metabolic, and alcohol misuse disorders

Debt Settlement FSD Pharma Neurodegenerative Disorders RSUs Biopharmaceutical Innovation

Accesswire

Published on 10/19/2026 at 13:01, 25 minutes ago

CoTec Holdings Corp. Notes HyProMag USA Deployment of Mobile Inserma System, Extending Hard Disk Drive Processing to Customer Sites Across the United States
Published on 10/19/2026 at 13:00, 26 minutes ago

Microbix Attending & Presenting at IPVS 2026
Published on 10/19/2026 at 13:00, 26 minutes ago

Stillwater Critical Minerals Files NI 43-101 Technical Report for the Updated Stillwater West Mineral Resource Estimate in Montana, USA
Published on 10/19/2026 at 13:00, 26 minutes ago

Rocky Shore's Antimony Discovery Enhances Lucky 13 Gold Zone at Gold Anchor
Published on 10/19/2026 at 13:00, 26 minutes ago

Nextech3D.ai Sponsors The Event Planner Expo 2026, Bringing its Recently Launched Agentic AI for Map D to the Event Industry

View all ACCESSWIRE

EQS Group

Published on 10/19/2026 at 13:00, 26 minutes ago

Amundi Asset Management: Delisting of 26 UCITS ETF Share Classes from London Stock Exchange
Published on 10/19/2026 at 12:35, 50 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 10/19/2026 at 12:35, 50 minutes ago

WESCAN GOLDFIELDS IDENTIFIES VISIBLE GOLD AT MUNRO LAKE AND COMPLETES UAV MAGNETIC SURVEY
Published on 10/19/2026 at 12:30, 55 minutes ago

26-year China-US friendship highlights grassroots efforts to combat desertification
Published on 10/19/2026 at 12:30, 56 minutes ago

Immunic Appoints Jaa Roberson as Chief People Officer

Les Echos

Published on 10/19/2026 at 11:45, 1 hour 40 minutes ago

Guillemot Corporation S.A. | Déclaration hebdomadaire des transactions sur actions propres du 12 au 16 octobre 2026
Published on 10/19/2026 at 11:45, 1 hour 40 minutes ago

Guillemot Corporation S.A. | Weekly report share buyback from October 12 to October 16, 2026
Published on 10/19/2026 at 10:49, 2 hours 36 minutes ago

261019 BENETEAU Transactions sur actions propres
Published on 10/19/2026 at 08:15, 5 hours 11 minutes ago

Carrefour strengthens its leadership in convenience retail in France with the acquisition of Codifrance
Published on 10/19/2026 at 08:15, 5 hours 11 minutes ago

Carrefour renforce son leadership dans le commerce de proximité en France avec l’acquisition de Codifrance

View all LES ECHOS COMFI WIRE